Lupin Launches Authorized Generic Version of Ravicti® in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.

Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Shares of Lupin Limited was last trading in BSE at Rs. 1940.05 as compared to the previous close of Rs. 1943.35. The total number of shares traded during the day was 19222 in over 2536 trades.

The stock hit an intraday high of Rs. 1965.00 and intraday low of 1934.65. The net turnover during the day was Rs. 37482007.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals GenericVersion Ravicti USA GlycerolPhenylbutyrate